Citations

Showing 10 of 108083 citations.

Diagnosis of Alzheimer’s disease and tauopathies on whole slide histopathology images using a weakly supervised deep learning algorithm
Yao, Gary, Martin, Nicholas B. , Castanedes‐Casey, Monica , Hwang, Tae Hyun , Koga, Shunsuke , Koga, Shunsuke , Kim, Minji , Sekiya, Hiroaki , Dickson, Dennis W.

Mayo Clinic

No container title available | January 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2459626/v2 Get It

Abstract Neuropathological assessment at autopsy is the gold standard for diagnosing neurodegenerative disorders. We aimed to develop a pipeline for diagnosing Alzheimer's disease and other tauopathies, including corticobasal degeneration, globular glial tauopathy, Pick’s disease, and progressive supranuclear palsy. We used deep learning (DL)-based approach called clustering-constrained-attention multiple instance learning (CLAM) on whole slide images (WSIs) of tau immunohistochemistry in three brain regions from 120 patients. We also augmented gradient-weighted class activation mapping (Grad-CAM) to the model for visualizing cellular-level evidence in the model’s decisions. The model using the sections of cingulate and superior frontal gyri achieved the highest area under the curve (0.970±0.037) and diagnostic accuracy (0.873±0.087). Grad-CAM showed the highest attention in known pathognomonic tau lesions for each disease (e.g., Pick bodies for Pick’s disease). Our findings supported the feasibility of the DL-based approach for the classification task on WSIs, which encouraged further investigation, especially focusing on clinicopathological correlation studies.
Circulating Progenitor Cells Are Associated With Bioprosthetic Aortic Valve Deterioration: A Preliminary Study
Kanaji, Yoshihisa , Ӧzcan, Ilke , Toya, Takumi , Gulati, Rajiv , Young, Melissa , Kakuta, Tsunekazu , Lerman, Lilach O. , Lerman, Amir , Ozcan, Ilke , Lerman, Amir , Toya, Takumi , Kanaji, Yoshihisa

Mayo Clinic

Journal of the American Heart Association | January 16, 2023 | Volume: 12 | Issue: 2 | Pages: No page available

10.1161/jaha.122.027364 | PMID 36645093 Get It

Background Mechanisms underlying bioprosthetic valve deterioration are multifactorial and incompletely elucidated. Reparative circulating progenitor cells, and conversely calcification‐associated osteocalcin expressing circulating progenitor cells, have been linked to native aortic valve deterioration. However, their role in bioprosthetic valve deterioration remains elusive. This study sought to evaluate the contribution of different subpopulations of circulating progenitor cells in bioprosthetic valve deterioration. Methods and Results This single‐center prospective study enrolled 121 patients who had peripheral blood mononuclear cells isolated before bioprosthetic aortic valve replacement and had an echocardiographic follow‐up ≥2 years after the procedure. Using flow cytometry, fresh peripheral blood mononuclear cells were analyzed for the surface markers CD34, CD133, and osteocalcin. Bioprosthetic valve deterioration was evaluated by hemodynamic valve deterioration (HVD) using echocardiography, which was defined as an elevated mean transprosthetic gradient ≥30 mm Hg or at least moderate intraprosthetic regurgitation. Sixteen patients (13.2%) developed HVD during follow‐up for a median of 5.9 years. Patients with HVD showed significantly lower levels of reparative CD34 + CD133 + cells and higher levels of osteocalcin‐positive cells than those without HVD (CD34 + CD133 + cells: 125 [80, 210] versus 270 [130, 420], P =0.002; osteocalcin‐positive cells: 3060 [523, 5528] versus 670 [180, 1930], P =0.005 respectively). Decreased level of CD34 + CD133 + cells was a significant predictor of HVD (hazard ratio, 0.995 [95% CI, 0.990%–0.999%]). Conclusions Circulating levels of CD34 + CD133 + cells and osteocalcin‐positive cells were significantly associated with the subsequent occurrence of HVD in patients undergoing bioprosthetic aortic valve replacement. Circulating progenitor cells might play a vital role in the mechanism, risk stratification, and a potential therapeutic target for patients with bioprosthetic valve deterioration.
Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
Panés, Julián , Loftus, Edward V. , Higgins, Peter , Yao, Xuan , Ilo, Dapo, Phillips, Charles M., Tran, Jacinda , González, Yuri Sánchez , Vermeire, Séverine , Loftus, Edward V , Panes, Julian , Vermeire, Séverine , Lindsay, James Oliver , Zhou, Wen

Mayo Clinic

Inflammatory Bowel Diseases | January 16, 2023 | Volume: 29 | Issue: 9 | Pages: 1421-1430

10.1093/ibd/izac260 | PMID 36645051 Get It

Abstract Background We evaluated the health-related quality of life (HRQoL) benefits of upadacitinib (UPA) induction and maintenance treatment in a phase 3 study of patients with ulcerative colitis (UC) across a broad range of patient-centered outcomes. Methods Patients received UPA 45 mg once daily or placebo as induction treatment for 8 weeks. Patients who achieved clinical response were rerandomized to receive once daily UPA 15 mg, 30 mg, or placebo as maintenance treatment for 52 weeks. The percentages of patients reporting a clinically meaningful within-person change from baseline in the Ulcerative Colitis Symptoms Questionnaire, Inflammatory Bowel Disease Questionnaire, Work Productivity and Impairment Questionnaire, 36-Item Short Form Survey, and European Quality of Life-5 Dimension 5 Levels were evaluated at weeks 2 and 8 of induction and at weeks 0 and 52 of maintenance. Results Significant improvements from baseline in all HRQoL measures except the Work Productivity and Impairment Questionnaire–absenteeism were achieved with UPA (P < .001) vs placebo as early as week 2 of induction. These improvements were sustained at week 52 with significantly more patients treated with either 15 mg or 30 mg UPA vs placebo achieving meaningful within-person change in the Ulcerative Colitis Symptoms Questionnaire; Inflammatory Bowel Disease Questionnaire; overall work impairment, presenteeism, and activity impairment; both 36-Item Short Form Survey Physical and Mental Component Summaries; and European Quality of Life-5 Dimension 5 Levels (P < .001). Conclusions Induction treatment with UPA 45 mg significantly improved HRQoL measures. A significantly higher percentage of patients who responded to induction treatment with UPA maintained clinically meaningful improvements consistently across a wide range of HRQoL outcomes after 52 weeks of maintenance therapy with UPA (15 mg and 30 mg) compared with placebo. (ClinicalTrials.gov, Numbers: NCT02819635, NCT03653026).
Prevalence and clinical features of orbital vascular anomalies in children
Torrado-Cobian, Laura A., Griepentrog, Gregory J. , Hodge, David O. , Mohney, Brian G., Torrado-Cobian, Laura A.

Mayo Clinic

Orbit | January 16, 2023 | Volume: 42 | Issue: 6 | Pages: 598-602

10.1080/01676830.2023.2166081 | PMID 36644978 Get It

Exploring therapeutic strategies for infantile neuronal axonal dystrophy (INAD/PARK14)
Lin, Guang , Tepe, Burak , McGrane, Geoff, Tipon, Regine , Croft, Gist F. , Panwala, Leena, Hope, Amanda, Liang, Agnes JH, Zuo, Zhongyuan , Byeon, Seul Kee , Wang, Lily , Pandey, Akhilesh , Tipon, Regine C , Bellen, Hugo J , Pandey, Akhilesh , Byeon, Seul Kee , Bellen, Hugo J.

Mayo Clinic

eLife | January 16, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.82555 | PMID 36645408 Get It

Infantile neuroaxonal dystrophy (INAD) is caused by recessive variants in PLA2G6 and is a lethal pediatric neurodegenerative disorder. Loss of the Drosophila homolog of PLA2G6 , leads to ceramide accumulation, lysosome expansion, and mitochondrial defects. Here, we report that retromer function, ceramide metabolism, the endolysosomal pathway, and mitochondrial morphology are affected in INAD patient-derived neurons. We show that in INAD mouse models, the same features are affected in Purkinje cells, arguing that the neuropathological mechanisms are evolutionary conserved and that these features can be used as biomarkers. We tested 20 drugs that target these pathways and found that Ambroxol, Desipramine, Azoramide, and Genistein alleviate neurodegenerative phenotypes in INAD flies and INAD patient-derived neural progenitor cells. We also develop an AAV-based gene therapy approach that delays neurodegeneration and prolongs lifespan in an INAD mouse model.
Item Response Analysis of the Financial Capacity Instrument-Short Form
Gerstenecker, Adam , Kennedy, Richard , Martin, Roy C. , Mackin, R. Scott , Weiner, Michael W. , Howell, Taylor, Petersen, Ronald C. , Roberson, Erik D. , Marson, Daniel , Roberson, Erik , Kennedy, Richard E , Zhang, Yue

Mayo Clinic

Archives of Clinical Neuropsychology | January 16, 2023 | Volume: 38 | Issue: 5 | Pages: 739-758

10.1093/arclin/acac112 | PMID 36644855 Get It

Abstract Objective The Financial Capacity Instrument-Short Form (FCI-SF) is a performance-based measure of everyday financial skills that takes 15 min to administer. Although the FCI-SF has demonstrated excellent psychometric properties, advanced psychometric methods such as item response theory (IRT) can provide important information on the performance of individual test items in measuring financial capacity and in distinguishing between healthy and cognitively impaired individuals. Method Participants were 272 older adults diagnosed with mild cognitive impairment (MCI) and 1,344 cognitively healthy controls recruited from the Mayo Clinic Study of Aging at the Mayo Clinic in Rochester, Minnesota and also from the Cognitive Observations in Seniors study at the University of Alabama at Birmingham. Participants in each study were administered the FCI-SF, which evaluates coin/currency calculation, financial conceptual knowledge, use of a checkbook/register, and use of a bank statement. Results A unidimensional two-parameter logistic model best fit the 37 FCI-SF Test items, and most FCI-SF items fit the unidimensional two-parameter model well. The results indicated that all FCI-SF items robustly distinguished cognitively healthy controls from persons with MCI. Conclusions The study results showed that the FCI-SF performed well under IRT analysis, further highlighted the psychometric properties of the FCI-SF as a valid and reliable measure of financial capacity, and demonstrated the clinical utility of the FCI-SF in distinguishing between cognitively normal and cognitively impaired individuals.
Extracellular vesicle‑mediated miR‑126‑3p transfer contributes to inter‑cellular communication in the liver tumor microenvironment
Moirangthem, Anuradha, Gondaliya, Piyush , Sayyed, Adil Ali , Driscoll, Julia , Yan, Irene K. , Ali Sayyed, Adil , Patel, Tushar

Mayo Clinic

International Journal of Oncology | January 16, 2023 | Volume: 62 | Issue: 2 | Pages: No page available

10.3892/ijo.2023.5479 | PMID 36660950 Get It

Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)
Núñez‐Gil, Iván J. , Feltes, Gisela , Viana‐Llamas, María C. , Romero, Rodolfo , Alfonso‐Rodríguez, Emilio , Uribarri, Aitor , Santoro, Francesco , Becerra‐Muñoz, Víctor Manuel , Pepe, Martino , Castro‐Mejía, Alex F. , Signes‐Costa, Jaime , González, Adelina , Marı́n, Francisco , López‐País, Javier , Cerrato, Enrico , Vázquez-Cancela, Olalla , Espejo‐Paeres, Carolina , Masjuan, Álvaro López, Velicki, Lazar , El‐Battrawy, Ibrahim , Pérez‐Villacastín, Julián , Alfonso-Rodríguez, Emilio , Santoro, Francesco , Pepe, Martino , Castro Mejía, Alex Fernando , Gonzalez, Adelina , Marín, Francisco , Cerrato, Enrico , Espejo-Paeres, Carolina , Velicki, Lazar , El-Battrawy, Ibrahim , Ramakrishna, Harish , Nuñez-Gil, Ivan Javier , Perez-Villacastín, Julian , Viana-Llamas, María C , Becerra-Muñoz, Víctor , Uribarri, Aitor , Raposeiras‐Roubín, Sergio , Fernández‐Ortíz, Antonio

Mayo Clinic

Journal of Clinical Medicine | January 16, 2023 | Volume: 12 | Issue: 2 | Pages: 706

10.3390/jcm12020706 | PMID 36675633 Get It

Background: Heart disease is linked to worse acute outcomes after coronavirus disease 2019 (COVID-19), although long-term outcomes and prognostic factor data are lacking. We aim to characterize the outcomes and the impact of underlying heart diseases after surviving COVID-19 hospitalization. Methods: We conducted an analysis of the prospective registry HOPE-2 (Health Outcome Predictive Evaluation for COVID-19-2, NCT04778020). We selected patients discharged alive and considered the primary end-point all-cause mortality during follow-up. As secondary main end-points, we included any readmission or any post-COVID-19 symptom. Clinical features and follow-up events are compared between those with and without cardiovascular disease. Factors with p < 0.05 in the univariate analysis were entered into the multivariate analysis to determine independent prognostic factors. Results: HOPE-2 closed on 31 December 2021, with 9299 patients hospitalized with COVID-19, and 1805 died during this acute phase. Finally, 7014 patients with heart disease data were included in the present analysis, from 56 centers in 8 countries. Heart disease (+) patients were older (73 vs. 58 years old), more frequently male (63 vs. 56%), had more comorbidities than their counterparts, and suffered more frequently from post-COVID-19 complications and higher mortality (OR heart disease: 2.63, 95% CI: 1.81–3.84). Vaccination was found to be an independent protector factor (HR all-cause death: 0.09; 95% CI: 0.04–0.19). Conclusions: After surviving the acute phase, patients with underlying heart disease continue to present a more complex clinical profile and worse outcomes including increased mortality. The COVID-19 vaccine could benefit survival in patients with heart disease during follow-up.
Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis
Taweesedt, Pahnwat , Lertjitbanjong, Ploypin , Eksombatchai, Dararat , Charoenpong, Prangthip , Moua, Teng , Tangpanithandee, Supawit , Petnak, Tananchai , Tangpanithandee, Supawit , Petnak, Tananchai , Taweesedt, Pahnwat Tonya , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | January 16, 2023 | Volume: 12 | Issue: 2 | Pages: 655

10.3390/jcm12020655 | PMID 36675583 Get It

Antifibrotic treatment has been approved for reducing disease progression in fibrotic interstitial lung disease (ILD). As a result of increased bleeding risk, some experts suggest cessation of antifibrotics prior to lung transplantation (LT). However, extensive knowledge regarding the impact of antifibrotic treatment on postoperative complications remains unclear. We performed a comprehensive search of several databases from their inception through to 30 September 2021. Original studies were included in the final analysis if they compared postoperative complications, including surgical wound dehiscence, anastomosis complication, bleeding complications, and primary graft dysfunction, between those with and without antifibrotic treatment undergoing LT. Of 563 retrieved studies, 6 studies were included in the final analysis. A total of 543 ILD patients completing LT were included, with 161 patients continuing antifibrotic treatment up to the time of LT and 382 without prior treatment. Antifibrotic treatment was not significantly associated with surgical wound dehiscence (RR 1.05; 95% CI, 0.31–3.60; I2 = 0%), anastomotic complications (RR 0.88; 95% CI, 0.37–2.12; I2 = 31%), bleeding complications (RR 0.76; 95% CI, 0.33–1.76; I2 = 0%), or primary graft dysfunction (RR 0.87; 95% CI, 0.59–1.29; I2 = 0%). Finally, continuing antifibrotic treatment prior to LT was not significantly associated with decreased 1-year mortality (RR 0.80; 95% CI, 0.41–1.58; I2 = 0%). Our study suggests a similar risk of postoperative complications in ILD patients undergoing LT who received antifibrotic treatment compared to those not on antifibrotic therapy.
Xenotransplantation: Current Challenges and Emerging Solutions
Arabi, Tarek Ziad , Sabbah, Belal Nedal , Zhu, Xiangyang , Lerman, Lilach O. , Lerman, Lilach O , Arabi, Tarek , Lerman, Amir

Mayo Clinic

Cell Transplantation | January 16, 2023 | Volume: 32 | Issue: No issue available | Pages: No page available

10.1177/09636897221148771 | PMID 36644844 Get It

To address the ongoing shortage of organs available for replacement, xenotransplantation of hearts, corneas, skin, and kidneys has been attempted. However, a major obstacle facing xenotransplants is rejection due to a cycle of immune reactions to the graft. Both adaptive and innate immune systems contribute to this cycle, in which natural killer cells, macrophages, and T-cells play a significant role. While advancements in the field of genetic editing can circumvent some of these obstacles, biomarkers to identify and predict xenograft rejection remain to be standardized. Several T-cell markers, such as CD3, CD4, and CD8, are useful in both the diagnosis and prediction of xenograft rejection. Furthermore, an increase in the levels of various circulating DNA markers and microRNAs is also predictive of xenograft rejection. In this review, we summarize recent findings on the advancements in xenotransplantation, with a focus on pig-to-human, the role of immunity in xenograft rejection, and its biomarkers.